Lonsurf is not technically a “last resort,” but it is a later-line treatment, meaning it’s used after several other therapies have already been tried. For metastatic colorectal cancer, the FDA approval specifically requires that patients have already gone through chemotherapy regimens containing three major drug classes, plus a targeted biological therapy. For metastatic stomach cancer, patients need to have completed at least two prior lines of chemotherapy. So while Lonsurf isn’t the final option available, it does come late in the treatment sequence.
Where Lonsurf Falls in the Treatment Sequence
The FDA label spells out the prerequisites clearly. For colorectal cancer that has spread, you need to have already received chemotherapy built around three backbone drugs (fluoropyrimidine, oxaliplatin, and irinotecan), a therapy that targets blood vessel growth in tumors, and, if your tumor’s genetic profile qualifies, a therapy targeting a specific growth signal on cancer cells. Only after all of those have been tried is Lonsurf indicated.
For metastatic stomach or gastroesophageal junction cancer, the threshold is at least two prior chemotherapy lines that included a fluoropyrimidine, a platinum agent, and either a taxane or irinotecan. If the tumor produces a certain protein (HER2), targeted therapy for that should also have been tried first.
In practice, this means most patients starting Lonsurf have been living with and treating their cancer for months or years. But “later-line” doesn’t mean “nothing left.” There are still options if Lonsurf stops working.
How Lonsurf Works
Lonsurf is an oral tablet containing two active components that work as a team. The primary ingredient is a compound that mimics one of the building blocks of DNA. When cancer cells try to copy their DNA to divide, they incorporate this fake building block instead, which disrupts the copying process and stops the cells from multiplying. The second ingredient is a protective agent that prevents your body from breaking down the first compound too quickly, keeping it active in your system longer. This second component may also have its own anti-tumor effect by interfering with the formation of new blood vessels that tumors need to grow.
You take the tablets twice daily with food for five days, then take two days off, then another five days on, followed by a 16-day rest period to complete a 28-day cycle. This pattern repeats until the cancer progresses or side effects become unmanageable.
What the Clinical Trials Showed
In the landmark RECOURSE trial for metastatic colorectal cancer, patients taking Lonsurf lived a median of 7.1 months compared to 5.3 months for those receiving a placebo. That translates to a 32% reduction in the risk of death. These were patients whose cancer had already progressed through all standard treatments, so even modest survival gains carry real significance at this stage.
Results in stomach cancer followed a similar pattern. In the TAGS trial, median survival was 5.7 months with Lonsurf versus 3.6 months with placebo, a 31% reduction in the risk of death. Again, these were heavily pretreated patients with limited remaining options.
More recently, combining Lonsurf with bevacizumab (a drug that blocks tumor blood vessel growth) has shown meaningful improvements over Lonsurf alone in colorectal cancer. The SUNLIGHT trial found that the combination extended both overall survival and the time before the disease worsened, while also preserving patients’ quality of life and physical function for longer. This combination is now an FDA-approved option and has shifted how oncologists use Lonsurf, making it a more effective tool than it was as a standalone treatment.
How Lonsurf Compares to Regorafenib
Regorafenib is the other major drug approved for a similar point in the colorectal cancer treatment sequence. A retrospective study comparing the two found that Lonsurf had a notably better response rate (52.5% vs. 34.2%) and a higher rate of disease control (64.2% vs. 46.1%). Median overall survival was similar between them, at 7.5 months for Lonsurf and 7.1 months for regorafenib, but more Lonsurf patients were alive at the three- and four-month marks.
Tolerability is where the two drugs diverge most sharply. Only 8.2% of patients on Lonsurf had to stop treatment because of side effects, compared to 24.2% on regorafenib. Lonsurf patients were also far less likely to need dose reductions: 84% stayed on their original dose versus 64% of regorafenib patients. Regorafenib is particularly associated with hand-foot syndrome, a painful skin reaction on the palms and soles that was dramatically less common with Lonsurf. On the other hand, Lonsurf causes more blood cell count drops, particularly neutropenia (low white blood cells), which requires regular blood monitoring.
These differences often guide which drug an oncologist recommends first. The two can also be used sequentially, meaning trying one doesn’t prevent you from trying the other later.
Side Effects to Expect
The most significant side effect of Lonsurf is its impact on blood cell production. Neutropenia is the primary concern, occurring at severe levels more frequently than with many other oral cancer drugs. This means regular blood tests throughout treatment to monitor white blood cell counts. If counts drop too low, your oncologist may delay a cycle or adjust the dose.
Common everyday side effects include fatigue, nausea, decreased appetite, and diarrhea. Most patients find these manageable compared to the intravenous chemotherapy regimens they’ve already been through. The fact that Lonsurf is a pill taken at home, rather than an infusion requiring clinic visits, is a practical quality-of-life advantage for many patients at this stage of treatment.
What Comes After Lonsurf
If Lonsurf stops working, it’s not necessarily the end of the road. Several paths remain depending on your specific situation. If you haven’t already tried regorafenib, that’s a standard next step (and vice versa). For the roughly 4-5% of colorectal cancer patients whose tumors are microsatellite unstable, immunotherapy with a checkpoint inhibitor is an option, though it’s often used earlier in the sequence now.
Clinical trials represent another important avenue, particularly for patients who have exhausted approved therapies. Some oncologists also consider rechallenge strategies, where previously used chemotherapy combinations are reintroduced after a period off them, since tumors can sometimes regain sensitivity to drugs they’ve been away from. Salvage regimens combining older chemotherapy agents like mitomycin with oxaliplatin or irinotecan have also shown some activity, though the evidence base is smaller.
The key point is that being prescribed Lonsurf means your cancer has proven resistant to the first several lines of treatment, and the realistic goals of therapy shift toward extending life and maintaining its quality rather than achieving a cure. But it is not the final card to play, and for many patients it provides meaningful months of stable disease and preserved daily function.